drugset / Trial / NCT06975644
Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)
NaSingle-groupOpen-labelTreatment
Summary
Evaluating Bemotuzumab to improve the efficacy of neoadjuvant chemotherapy for Triple-Negative Breast Cancer (TNBC)
Timeline
- Start
- 2025-09-01
- Primary completion
- 2026-09-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bemotuzumab | Unknown | 1200 mg | — |
| Background | Carboplatin | Small molecule | 6 unknown | — |
| Background | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Background | Epirubicin | Small molecule | 90 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 260 mg/m2 | — |